Pular para o conteúdo
Menu
Mix Vale

Worldwide breakthrough in Kraków: DK-AT390HCl eliminates colon tumors without damaging normal cells in trials

Janderson Luiz
Por 4 min de leitura
Compartilhe
Câncer colorretal
Foto: Câncer colorretal - Foto: PonyWang/istock

Researchers from institutions in Kraków, in Polônia, developed a chemical compound calledDK-AT390HClwhich demonstrates high effectiveness in combating rak jelita grubego cells. The announcement took place in December 2025, with tests revealing that the substance selectively attacks cancer cells, preserving healthy ones. Liderado by dr. inż. Damian Kułaga from Politechnika Krakowska, the project involves collaboration with Uniwersytet Rolniczy w Krakowie and Instytut Immunologii i Terapii Doświadczalnej PAN.

Publicidade

O rak jelita grubegorepresents one of the main causes of cancer deaths in the world, with around 2 million new cases diagnosed annually and approximately 900 thousand deaths, according to data from 2022. The new molecule appears as a potential option to improve current treatments, which often cause significant side effects due to lack of selectivity.

In vitro and in vivo tests indicated that theDK-AT390HClsignificantly reduces tumor mass in animal models. The substance already has the protection of four patents granted and two requests in progress, in addition to prospects for European registration.

Publicidade

Mechanism of action of the molecule

O DK-AT390HClit acts precisely by interacting with a specific lipidowa kinaza present in cancer cells. Essa interaction blocks secondary biological processes, including autophagy, which allows tumor cells to survive in adverse conditions, such as during chemotherapy.

The researchers compare the operation to a lock and key system, where the molecule fits perfectly into the target enzyme. Essa precision explains the observed selectivity, with minimal damage to normal cells in direct comparisons.

  • Hamowanie autofagii prevents the self-defense of cancer cells.
  • Reduction of migration and formation of tumor colonies in laboratory tests.
  • Favorable initial safety profile in preliminary in vivo evaluations.

Compound selection process

The team synthesized more than 200 tryptamine-derived substances enriched with triazine and pyrimidine structures. Inicialmente, the compounds were evaluated for activity against triple negative Rak Piersi, but theDK-AT390HClit stood out in subsequent tests for rak jelita grubego.

Interdisciplinary collaborations have enabled detailed analyzes in both cancerous and normal cell lines. The substance showed elevated cytotoksyczność against strains such as SW480 and SW620, common in colorectal cancer studies.

These results motivated additional funding from European funds to advance biological research. The compound reached the TRL4 level of technological maturity, indicating feasibility for pre-clinical stages.

Publicidade

Global rak jelita grubego statistics

Colorectal cancer ranks third in worldwide incidence and second in oncological mortality. Fatores as a late diagnosis contribute to the spread of metastases, complicating treatment in advanced stages.

In Polônia, the disease mainly affects adults, but an increase is observed in age groups under 50 years old. Programas screening, such as colonoscopy, remains essential for early detection.

  • Around 2 million new cases per year globally.
  • Approximately 900,000 annual related deaths.
  • Reduced survival rate in metastatic stages.

Collaborations and funding

The project has support from institutions such as Narodowe Centrum Badań i Rozwoju and Fundacja na rzecz Nauki Polskiej. Parcerias between chemistry, biology and veterinary medicine accelerated development.

Researchers like Dr. Izabela Siemińska, from Uniwersytet Rolniczy, contributed expertise in immunooncology. Essas alliances strengthened experimental validations.

Current focus includes assessment of toxicity and additional molecular mechanisms. Discussões on commercialization involves the Politechnika Krakowska technology transfer center.

Intellectual protection achieved

Four patents already protect aspects of the synthesis and application ofDK-AT390HCl. Duas additional requests are under review, including the international PCT procedure.

This coverage reinforces the innovative potential of the molecule as a first-in-class candidate. The registrations cover specific compositions and therapeutic uses against colorectal tumors.

The perspective of European protection expands the possibilities of partnerships with the pharmaceutical industry. Tais alliances would be necessary to fund future clinical phases.

Preliminary in vivo tests

Evaluations in animal models confirmed a substantial reduction in tumor mass. The compound demonstrated a favorable maximum tolerated dose in initial studies.

Molecular research in tumor tissues has validated the blockade of pathways associated with cancer progression. Esses data supports continuation to preclinical refinements.

Results indicate that guzos responded with almost complete regression in certain protocols. Continuous Monitoramento checks consistency of these effects.

Next steps in development

The team is looking for pharmaceutical partners to advance to the clinical phases, which require high investments. Additional Estudos focus on confirming selectivity in human tissues.

The compound represents an advance in targeted therapies for resistant cancers. Pesquisas parallels explore combinations with existing treatments.

Monitoring of common mutations, such as KRAS and BRAF, integrates future analyses. Esses efforts aim to maximize clinical applicability.

Publicidade

Janderson Luiz é colaborador da redação do Mix Vale, portal de notícias com cobertura de Brasil e mundo. Produz conteúdo nas editorias de economia e benefícios, com foco em informação de serviço para o leitor brasileiro. Escreve para o portal desde 2024. Formação: Atleta Profissional de Futebol

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto